• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Pathology oncology research: POR >Comparison of Native Aspirates and Cytological Smears Obtained by EUS-Guided Biopsies for Effective DNA/RNA Marker Testing in Pancreatic Cancer
【24h】

Comparison of Native Aspirates and Cytological Smears Obtained by EUS-Guided Biopsies for Effective DNA/RNA Marker Testing in Pancreatic Cancer

机译：通过EUS引导活组织检查在胰腺癌中获得有效DNA / RNA标记试验获得的本机吸气和细胞学涂片的比较

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

We compare two types of pancreatic carcinoma samples obtained by EUS-guided fine needle biopsy (EUS-FNB) in terms of the success rates and clinical validity of analysis of two most commonly investigated DNA/RNA pancreatic cancer markers, KRAS mutations and miR-21 expression. 118 patients with pancreatic ductal adenocarcinoma underwent EUS-FNB. The collected sample was divided, one part was stored in a stabilizing solution as native aspirate (EUS-FNA) and second part was processed into the cytological smear (EUS-FNC). DNA/RNA extraction was followed by analysis of KRAS mutations and miR-21 expression. For both sample types, the yields of DNA/RNA extraction and success rates of KRAS mutation and miRNA expression were evaluated. Finally, the resulting KRAS mutation frequency and miR-21 prognostic role were compared to literature data from tissue resections. The overall amount of isolated DNA/RNA from EUS-FNC was lower compared to the EUS-FNA, average yield 10 ng vs 147 ng for DNA and average yield 164 vs. 642 ng for RNA, but the success rates for KRAS and miR-21 analysis was 100% for both sample types. The KRAS-mutant detection frequency in EUS-FNC was 12% higher than in EUS-FNA (90 vs 78%). The prognostic role of miR-21 was confirmed in EUS-FNC (p = 0.02), but did not reach statistical significance in EUS-FNA (p = 0.06). Although both types of EUS-FNB samples are suitable for DNA/RNA extraction and subsequent DNA mutation and miRNA expression analysis, reliable results with clinical validity were only obtained for EUS-FNC.
机译：我们在分析两种最常见的DNA / RNA胰腺癌标志物，KRAS突变和MIR-21的成功率和临床有效性方面，比较两种类型的胰腺癌样品（EUS-FNB）获得的胰腺癌样品表达。 118例胰腺导管腺癌患者接受EUS-FNB。将收集的样品分开，将一个部分储存在稳定溶液中，因为天然吸气（EUS-FNA）和第二部分被加工到细胞学涂片（EUS-FNC）中。然后通过分析KRAS突变和miR-21表达进行DNA / RNA提取。对于两种样品类型，评估了DNA / RNA提取的产量和KRAS突变和MiRNA表达的成功率。最后，将得到的KRAS突变频率和miR-21预后作用与来自组织切除的文献数据进行比较。与EUS-FNC的分离DNA / RNA的总量与EUS-FNA相比，平均产率为10ng与147ng的DNA，平均产率为164与RNA，但克拉斯和MIR的成功率 - 对于两种样品类型，21分析为100％。 EUS-FNC中的KRAS-突变检测频率比EUS-FNA高12％（90 vs 78％）。 MiR-21的预后作用在EUS-FNC（P = 0.02）中确认，但在EUS-FNA中没有达到统计学意义（p = 0.06）。尽管两种类型的EUS-FNB样品适用于DNA / RNA提取和随后的DNA突变和miRNA表达分析，但仅获得EUS-FNC的可靠结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号